Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.

Mancini JA, Prasit P, Coppolino MG, Charleson P, Leger S, Evans JF, Gillard JW, Vickers PJ.

Mol Pharmacol. 1992 Feb;41(2):267-72.

PMID:
1538707
2.

5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors.

Evans JF, Lévillé C, Mancini JA, Prasit P, Thérien M, Zamboni R, Gauthier JY, Fortin R, Charleson P, MacIntyre DE, et al.

Mol Pharmacol. 1991 Jul;40(1):22-7.

PMID:
1857337
3.

Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors.

Vickers PJ, Adam M, Charleson S, Coppolino MG, Evans JF, Mancini JA.

Mol Pharmacol. 1992 Jul;42(1):94-102.

PMID:
1635556
4.

Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.

Charleson S, Prasit P, Léger S, Gillard JW, Vickers PJ, Mancini JA, Charleson P, Guay J, Ford-Hutchinson AW, Evans JF.

Mol Pharmacol. 1992 May;41(5):873-9.

PMID:
1588922
5.

A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.

Prasit P, Belley M, Blouin M, Brideau C, Chan C, Charleson S, Evans JF, Frenette R, Gauthier JY, Guay J, et al.

J Lipid Mediat. 1993 Mar-Apr;6(1-3):239-44.

PMID:
8357985
6.

The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein.

Mancini JA, Coppolino MG, Klassen JH, Charleson S, Vickers PJ.

Life Sci. 1994;54(9):PL137-42.

PMID:
8114608
7.

5-lipoxygenase-activating protein is an arachidonate binding protein.

Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, Perrier H, Wang Z, Prasit P, Vickers PJ.

FEBS Lett. 1993 Mar 8;318(3):277-81.

8.

Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors.

Vickers PJ, Adam M, Charleson S, Abramovitz M, O'Neill G, Mancini JA.

J Lipid Mediat. 1993 Mar-Apr;6(1-3):31-42.

PMID:
8357989
9.

Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein.

Charleson S, Evans JF, Léger S, Perrier H, Prasit P, Wang Z, Vickers PJ.

Eur J Pharmacol. 1994 May 17;267(3):275-80.

PMID:
8088366
10.

Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.

Brideau C, Chan C, Charleson S, Denis D, Evans JF, Ford-Hutchinson AW, Fortin R, Gillard JW, Guay J, Guévremont D, et al.

Can J Physiol Pharmacol. 1992 Jun;70(6):799-807.

PMID:
1330258
11.

Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors.

Kolasa T, Bhatia P, Brooks CD, Hulkower KI, Bouska JB, Harris RR, Bell RL.

Bioorg Med Chem. 1997 Mar;5(3):507-14.

PMID:
9113329
12.

FLAP: a novel drug target for inhibiting the synthesis of leukotrienes.

Ford-Hutchinson AW.

Trends Pharmacol Sci. 1991 Feb;12(2):68-70.

PMID:
2024291
13.

Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.

Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW.

Science. 2007 Jul 27;317(5837):510-2. Epub 2007 Jun 28.

14.

Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.

Gupta N, Nicholson DW, Ford-Hutchinson AW.

Can J Physiol Pharmacol. 1997 Oct-Nov;75(10-11):1212-9.

PMID:
9431445
15.

Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.

Macdonald D, Brideau C, Chan CC, Falgueyret JP, Frenette R, Guay J, Hutchinson JH, Perrier H, Prasit P, Riendeau D, Tagari P, Thérien M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2023-7. doi: 10.1016/j.bmcl.2008.01.105. Epub 2008 Feb 2.

PMID:
18276139
16.
17.

Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.

Frenette R, Hutchinson JH, Léger S, Thérien M, Brideau C, Chan CC, Charleson S, Ethier D, Guay J, Jones TR, McAuliffe M, Piechuta H, Riendeau D, Tagari P, Girard Y.

Bioorg Med Chem Lett. 1999 Aug 16;9(16):2391-6.

PMID:
10476875
18.

Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase.

Hatzelmann A, Fruchtmann R, Mohrs KH, Raddatz S, Matzke M, Pleiss U, Keldenich J, Müller-Peddinghaus R.

Agents Actions. 1994 Nov;43(1-2):64-8. Review.

PMID:
7741044
20.

Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.

Hutchinson JH, Charleson S, Evans JF, Falgueyret JP, Hoogsteen K, Jones TR, Kargman S, Macdonald D, McFarlane CS, Nicholson DW, et al.

J Med Chem. 1995 Oct 27;38(22):4538-47.

PMID:
7473582
Items per page

Supplemental Content

Write to the Help Desk